Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Immix Biopharma reported an 89% complete response rate (40/45) in an interim NEXICART-2 update. Four MRD-negative pending patients may lift CR up to 98% (44/45). No relapses or neurotoxicity observed to-date; final readout and BLA submission planned in 2027.Material DetailsContext by AI AnalystThis…
Immix Biopharma said NXC-201 interim results in relapsed or refractory AL amyloidosis showed an 89% complete response rate across patients, with no relapses reported so far among those with deep responses and no neurotoxicity or enterocolitis seen to date. Final NEXICART-2 readout and BLA submission are planned for mid
Immix Biopharma said its interim update across all NEXICART-2 patients showed an 89% complete response rate, with MRD-negativity suggesting potential to reach up to a 98% complete response rate, supporting potential best-in-class therapy for relapsed/refractory AL amyloidosis.